scholarly article | Q13442814 |
P50 | author | Chetan Eknath Chitnis | Q5094149 |
Ruth O Payne | Q56441184 | ||
James S McCarthy | Q64025726 | ||
Sean C Elias | Q84616864 | ||
Eleanor Berrie | Q91783433 | ||
Alison M. Lawrie | Q109926029 | ||
Thomas D Otto | Q30503446 | ||
Matthew K. Higgins | Q43240638 | ||
Simon J. Draper | Q47576805 | ||
Nick J Edwards | Q55172988 | ||
Thomas Jørgensen | Q56379466 | ||
P2093 | author name string | Alfredo Nicosia | |
Jing Jin | |||
Ian D Poulton | |||
Sarah Moyle | |||
David Llewellyn | |||
Rachel Roberts | |||
Simone C de Cassan | |||
Adrian Vs Hill | |||
Geneviève M Labbé | |||
Sarah E Silk | |||
Kathryn H Milne | |||
Ryan Farid | |||
Willem A de Jongh | |||
Daniel Gw Alanine | |||
Thomas A Rawlinson | |||
A Rushdi Shakri | |||
P2860 | cites work | Evidence and implications of mortality associated with acute Plasmodium vivax malaria | Q21032494 |
Red blood cell invasion by Plasmodium vivax: structural basis for DBP engagement of DARC | Q21131367 | ||
A long neglected world malaria map: Plasmodium vivax endemicity in 2010 | Q21144495 | ||
Glycan masking of Plasmodium vivax Duffy Binding Protein for probing protein binding function and vaccine development | Q21558777 | ||
The Resistance Factor to Plasmodium vivax in Blacks | Q22250916 | ||
Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium Vivax | Q24273364 | ||
A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA | Q24289279 | ||
Production of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line system | Q26700012 | ||
Dimerization of Plasmodium vivax DBP is induced upon receptor binding and drives recognition of DARC | Q27670749 | ||
Plasmodium vivax Controlled Human Malaria Infection - Progress and Prospects | Q28066456 | ||
Plasmodium vivax vaccine research - we've only just begun | Q28079136 | ||
The Presence, Persistence and Functional Properties of Plasmodium vivax Duffy Binding Protein II Antibodies Are Influenced by HLA Class II Allelic Variants | Q28396379 | ||
Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors | Q28731894 | ||
Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults | Q28744149 | ||
Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. | Q33350210 | ||
Mapping epitopes of the Plasmodium vivax Duffy binding protein with naturally acquired inhibitory antibodies | Q33676028 | ||
Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure | Q34257253 | ||
Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51 | Q34546201 | ||
Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial | Q34600955 | ||
A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS. | Q34734075 | ||
A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys | Q34978590 | ||
Antibody responses and avidity of naturally acquired anti-Plasmodium vivax Duffy binding protein (PvDBP) antibodies in individuals from an area with unstable malaria transmission | Q35031922 | ||
Whole genome sequencing of field isolates reveals a common duplication of the Duffy binding protein gene in Malagasy Plasmodium vivax strains | Q35054176 | ||
De novo assembly of a field isolate genome reveals novel Plasmodium vivax erythrocyte invasion genes | Q35068049 | ||
Plasmodium vivax: restricted tropism and rapid remodeling of CD71-positive reticulocytes | Q35460685 | ||
Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors | Q35623459 | ||
Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector | Q35741984 | ||
Conserved and variant epitopes of Plasmodium vivax Duffy binding protein as targets of inhibitory monoclonal antibodies | Q35805433 | ||
Plasmodium vivax Transmission in Africa | Q35847037 | ||
Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy | Q35937418 | ||
Independent Origin and Global Distribution of Distinct Plasmodium vivax Duffy Binding Protein Gene Duplications | Q36178527 | ||
Plasmodium vivax but Not Plasmodium falciparum Blood-Stage Infection in Humans Is Associated with the Expansion of a CD8+ T Cell Population with Cytotoxic Potential. | Q36215933 | ||
A reliable ex vivo invasion assay of human reticulocytes by Plasmodium vivax | Q36225497 | ||
Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults | Q36347381 | ||
ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans | Q36460499 | ||
Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection | Q36751523 | ||
Effective induction of high-titer antibodies by viral vector vaccines | Q36770379 | ||
Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity | Q36835495 | ||
Preclinical assessment of the receptor-binding domain of Plasmodium vivax Duffy-binding protein as a vaccine candidate in rhesus macaques. | Q36867704 | ||
Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01 | Q36871970 | ||
Broadly neutralizing epitopes in the Plasmodium vivax vaccine candidate Duffy Binding Protein | Q36978206 | ||
Targeting the Plasmodium vivax Duffy-binding protein. | Q37006600 | ||
Red blood cell polymorphism and susceptibility to Plasmodium vivax | Q37058815 | ||
A Novel Erythrocyte Binding Protein of Plasmodium vivax Suggests an Alternate Invasion Pathway into Duffy-Positive Reticulocytes | Q37208395 | ||
Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants | Q37229742 | ||
Strain-specific duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous plasmodium vivax strains in Papua New Guinean children | Q37333369 | ||
Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection | Q37641378 | ||
Erythrocyte and reticulocyte binding-like proteins of Plasmodium falciparum | Q37969486 | ||
Clinical development of Modified Vaccinia virus Ankara vaccines | Q38092470 | ||
Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets | Q38096489 | ||
Recent developments in malaria vaccinology | Q38441542 | ||
Development of vaccines for Plasmodium vivax malaria | Q38597276 | ||
A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory | Q41672361 | ||
Antibodies raised against receptor-binding domain of Plasmodium knowlesi Duffy binding protein inhibit erythrocyte invasion | Q42051683 | ||
Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaques | Q42260871 | ||
Malaria vaccine technology roadmap | Q43650366 | ||
Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria | Q44164504 | ||
Naturally Acquired Binding-Inhibitory Antibodies to Plasmodium vivax Duffy Binding Protein and Clinical Immunity to Malaria in Rural Amazonians. | Q46926980 | ||
Naturally acquired inhibitory antibodies to Plasmodium vivax Duffy binding protein are short-lived and allele-specific following a single malaria infection | Q47812027 | ||
Age-dependent cellular immune responses to Plasmodium vivax Duffy binding protein in humans | Q47911727 | ||
Targeting TLRs expands the antibody repertoire in response to a malaria vaccine | Q47986739 | ||
Targeted deletion of Plasmodium knowlesi Duffy binding protein confirms its role in junction formation during invasion | Q48004710 | ||
Comparison of IgG reactivities to Plasmodium vivax merozoite invasion antigens in a Brazilian Amazon population. | Q48013929 | ||
Development of quantitative receptor-ligand binding assay for use as a tool to estimate immune responses against Plasmodium vivax Duffy binding protein Region II. | Q48019458 | ||
P433 | issue | 12 | |
P921 | main subject | Plasmodium vivax | Q311376 |
P577 | publication date | 2017-06-15 | |
P1433 | published in | JCI insight | Q27727187 |
P1476 | title | Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies | |
P478 | volume | 2 |
Q98187263 | A Humanized Mouse Model for Plasmodium vivax to Test Interventions that Block Liver Stage to Blood Stage Transition and Blood Stage Infection |
Q89655220 | A Plasmodium vivax experimental human infection model for evaluating the efficacy of interventions |
Q89790993 | Amplification of Duffy binding protein-encoding gene allows Plasmodium vivax to evade host anti-DBP humoral immunity |
Q64967806 | Born to sweet delight: Using natural models of malaria protection to understand and neutralize P. falciparum pathogenesis. |
Q92727025 | Clinical expression and antigenic profiles of a Plasmodium vivax vaccine candidate: merozoite surface protein 7 (PvMSP-7) |
Q56342168 | Diversity pattern of Duffy binding protein sequence among Duffy-negatives and Duffy-positives in Sudan |
Q92797716 | Human antibodies against DBP |
Q47279598 | Human genetics of infectious diseases: Unique insights into immunological redundancy |
Q47576664 | Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions |
Q92827824 | Identification and Characterization of Functional Human Monoclonal Antibodies to Plasmodium vivax Duffy-Binding Protein |
Q56358725 | IgG Responses to the Plasmodium falciparum Antigen VAR2CSA in Colombia Are Restricted to Pregnancy and Are Not Induced by Exposure to Plasmodium vivax |
Q56362064 | Malaria Vaccines: Recent Advances and New Horizons |
Q57299814 | Malaria vaccine candidate based on Duffy-binding protein elicits strain transcending functional antibodies in a Phase I trial |
Q96607419 | Malaria vaccines since 2000: progress, priorities, products |
Q59800434 | Novel Strategies for Malaria Vaccine Design |
Q55382338 | Persistence of Long-lived Memory B Cells specific to Duffy Binding Protein in individuals exposed to Plasmodium vivax. |
Q64947201 | Rapid and iterative genome editing in the malaria parasite Plasmodium knowlesi provides new tools for P. vivax research. |
Q65937995 | Structural basis for inhibition of Plasmodium vivax invasion by a broadly neutralizing vaccine-induced human antibody |
Q92325722 | Structural basis for neutralization of Plasmodium vivax by naturally acquired human antibodies that target DBP |
Q55429433 | Structural patterns of selection and diversity for Plasmodium vivax antigens DBP and AMA1. |
Q92447357 | The acquisition of long-lived memory B cell responses to merozoite surface protein-8 in individuals with Plasmodium vivax infection |
Q89802320 | The enigmatic mechanisms by which Plasmodium vivax infects Duffy-negative individuals |